Does Harvard Pilgrim Health Care Cover Eliquis?

What Eliquis Is and Why Insurers Scrutinize It

Eliquis (apixaban) is an oral Factor Xa inhibitor approved by the FDA for four primary indications: reducing stroke and systemic embolism risk in non-valvular atrial fibrillation (AFib), treating deep vein thrombosis (DVT) and pulmonary embolism (PE), reducing the risk of recurrent DVT and PE, and preventing DVT following hip or knee replacement surgery [1]. Because apixaban has no approved generic, its wholesale acquisition cost remains high, which pushes most commercial insurers to place it on a non-preferred brand tier.

The ARISTOTLE Trial and Why Apixaban Became Standard of Care

The key ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced the composite endpoint of stroke or systemic embolism by 21% compared with dose-adjusted warfarin (1.27% vs. 1.60% per year; hazard ratio 0.79; 95% CI 0.66 to 0.95; P<0.001 for non-inferiority, P=0.01 for superiority) [2]. Major bleeding occurred in 2.13% of apixaban patients per year versus 3.09% with warfarin (P<0.001) [2]. Those numbers helped cement apixaban as a first-line anticoagulant in the 2023 ACC/AHA Atrial Fibrillation Guideline, which gives a Class I recommendation to direct oral anticoagulants (DOACs) over warfarin in eligible AFib patients [3].

AMPLIFY and VTE Indications

For acute VTE, the AMPLIFY trial (N=5,395) showed apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) for the primary efficacy outcome, with significantly less major bleeding (0.6% vs. 1.8%; relative risk 0.31; 95% CI 0.17 to 0.55; P<0.001) [4]. These trial results underpin guideline support and, by extension, the clinical justification that prescribers use in prior authorization letters.

How Harvard Pilgrim Health Care Structures Its Formulary

Harvard Pilgrim Health Care, now operating under Point32Health after merging with Tufts Health Plan, maintains separate formularies for its commercial HMO/PPO products, its Medicare Advantage plans, and its Medicaid/ConnectiCare products [5]. Formulary tier placement for Eliquis can differ across those lines.

Commercial Plan Formulary Tiers

On HPHC commercial plans (both HMO and PPO), Eliquis historically appears at Tier 3 (non-preferred brand) or occasionally Tier 4 (specialty). Tier 3 cost-sharing for HPHC commercial plans commonly runs $50, $100 per 30-day fill at preferred pharmacies, though the exact copay depends on the employer's benefit design. Some self-funded employer plans that carve out their pharmacy benefit through a separate PBM may place Eliquis differently, so confirming tier placement through the member portal at harvardpilgrim.org or calling the number on the back of your insurance card is the most reliable first step.

Medicare Advantage Formulary Tiers

On HPHC Medicare Advantage products, Eliquis typically lands at Tier 4 (non-preferred drug) under standard Part D rules. The Centers for Medicare and Medicaid Services (CMS) sets cost-sharing guardrails, but Tier 4 cost-sharing in the coverage gap (now capped at 25% for 2024 under the Inflation Reduction Act) can still translate to meaningful out-of-pocket spending for fixed-income seniors [6]. All Part D formularies must cover at least two drugs in each therapeutic category per CMS rules, meaning some DOAC (rivaroxaban, for instance) may be preferred over apixaban on a given plan's tier structure [7].

Medicaid and ConnectiCare Products

State Medicaid programs that use HPHC/ConnectiCare as a managed care organization set their own preferred drug lists. In Connecticut and Massachusetts, apixaban has received preferred status on some state PDLs in recent years, which can reduce or eliminate prior authorization burdens for Medicaid enrollees. Checking the state-specific preferred drug list directly is the most accurate approach.

Prior Authorization Requirements for Eliquis Under HPHC

Prior authorization (PA) is a coverage pre-approval process that HPHC (like most large insurers) uses for higher-cost brand drugs. For Eliquis, PA criteria typically require documentation of several clinical elements.

Common PA Criteria HPHC Uses

1. Confirmed diagnosis. The chart note or claim must reflect an FDA-approved indication for apixaban: non-valvular AFib, DVT, PE, or post-surgical VTE prophylaxis [1].
2. Renal function documentation. Because dosing adjustments apply when two of three criteria are met (age 80+, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher), HPHC PA forms commonly request recent lab values [8].
3. Trial of warfarin or clinical reason to avoid it. Step therapy provisions on some HPHC plan designs require a documented trial of warfarin (typically 90 days) or a documented contraindication such as labile INR, frequent travel preventing monitoring, or documented warfarin failure. The ACC notes that patients with time in therapeutic range below 65 to 70% on warfarin represent a strong clinical argument for switching to a DOAC [3].
4. Prescriber attestation. The prescribing physician must attest that the patient meets criteria, often accompanied by a clinical summary letter.

Step Therapy and How to Bypass It

Step therapy policies require a patient to try a preferred (lower-tier) drug before the plan will cover the requested drug at the preferred cost-sharing level. For anticoagulants, that commonly means warfarin first. Federal law now provides some protection: the Restoring the Patient's Voice Act and state-level step therapy reform laws (Massachusetts enacted step therapy protections in 2018) require insurers to grant a step therapy exception when [9]:

• The patient previously tried the required drug and it failed or caused an adverse reaction.
• The required drug is contraindicated.
• The patient is clinically stable on the requested drug (continuity-of-care provision).

Prescribers can file a step therapy exception alongside the PA request. Documenting a specific clinical reason (such as "patient had INR values ranging 1.4 to 3.8 over 6 months on warfarin, time in therapeutic range 52%") carries more weight than generic language.

What a Prior Authorization Letter Should Include

A well-constructed PA letter meaningfully increases approval odds. The American College of Cardiology recommends that PA letters for DOACs cite the specific guideline class of recommendation, trial data, and patient-specific factors that make the alternative drug unsuitable [3].

The HealthRX PA Letter Framework for Apixaban

A PA letter for Eliquis under HPHC should include, in this order:

1. Patient identifiers and diagnosis code (e.g., ICD-10 I48.0 for paroxysmal AFib).
2. Specific clinical indication and duration of anticoagulation planned.
3. Renal function and weight from the most recent labs (within 6 months).
4. Warfarin trial documentation or a specific contraindication with supporting evidence.
5. Guideline citation. For AFib, cite the 2023 ACC/AHA Guideline Class I recommendation for DOACs [3]. For VTE, cite the 2021 American Society of Hematology VTE guideline, which gives a conditional recommendation favoring apixaban over warfarin for most VTE patients given its bleeding profile [10].
6. Trial data. Reference ARISTOTLE for AFib [2] or AMPLIFY for VTE [4] with specific percentages.
7. Patient-specific barriers to warfarin (travel, monitoring burden, labile INR history).
8. Requested approval duration (typically 12 months with annual renewal).

Harvard Pilgrim's Medical Director for pharmacy policy has stated publicly that "clinical specificity in PA requests correlates directly with faster approval turnarounds," a principle echoed across the payer industry [11].

What Apixaban Costs Without Coverage and How to Reduce It

The average wholesale price (AWP) of Eliquis 5 mg twice daily (60 tablets per 30 days) runs approximately $550, $620 per month as of 2024 [12]. For patients whose claims are denied or who are in a high cost-sharing tier, several programs exist.

Bristol Myers Squibb Patient Assistance Program

Bristol Myers Squibb and Pfizer co-market Eliquis and jointly operate the Eliquis 360 Support program. Patients who are uninsured or underinsured and meet income criteria (generally at or below 400% of the federal poverty level) may receive Eliquis at no cost [13]. The application is available at bms.com and requires a prescriber signature plus proof of income.

Eliquis Co-Pay Card

For commercially insured patients (not Medicare or Medicaid), the Eliquis co-pay card can reduce out-of-pocket costs to as low as $10 per month for eligible patients. The co-pay card does not apply to government-funded insurance programs per federal anti-kickback statute requirements [14].

Mark Cuban's Cost Plus Drugs

As of early 2025, apixaban does not have an FDA-approved generic, so Cost Plus Drugs (costplusdrugs.com) cannot offer a meaningful discount. If a generic version receives FDA approval, that field will shift substantially. The FDA lists no approved generic apixaban applications as of the current review date [15].

GoodRx and Discount Cards

GoodRx and similar discount programs can bring the retail price of Eliquis to approximately $450, $520 per month at major chain pharmacies. This is rarely competitive with insurance coverage but serves as a bridge option during a PA appeal.

How to Appeal a Denial

HPHC, like all insurers in states subject to the ACA, must provide a written explanation of denial and a clear appeals process. Nationally, roughly 30 to 40% of initial PA denials are overturned on first internal appeal [16]. The process for HPHC typically runs as follows.

Internal Appeal

File within 60 days of the denial notice. Submit new or additional clinical documentation. An expedited appeal (decision within 72 hours) is available when the standard timeframe would seriously jeopardize health [17]. Include the PA letter framework above and request a peer-to-peer review with the HPHC medical director reviewing the case.

External Review

If the internal appeal is denied, Massachusetts and Connecticut law (where HPHC operates most of its commercial business) require access to independent external review through a state-certified independent review organization (IRO). The IRO decision is binding on the insurer [18]. For Medicare Advantage denials, CMS operates its own appeals ladder through the Office of Medicare Hearings and Appeals (OMHA) [19].

Peer-to-Peer Review

Peer-to-peer (P2P) review allows the prescribing physician to speak directly with the HPHC reviewing physician. Studies published in the Journal of the American Medical Association suggest that P2P reviews resolve a meaningful percentage of initial denials without requiring a formal appeal [20]. Schedule the P2P call within 5 business days of a denial to keep timelines manageable.

Clinical Alternatives HPHC May Prefer Over Eliquis

When step therapy applies, HPHC may prefer one of the following anticoagulants before Eliquis coverage at the preferred tier is granted.

Warfarin (Coumadin)

Warfarin remains the only oral anticoagulant with a widely available generic and a decades-long evidence base. It requires INR monitoring every 4 to 12 weeks once stable. The 2023 ACC/AHA guideline gives warfarin a lower class of recommendation than DOACs for most AFib patients when a DOAC is an option [3]. Patients with mechanical heart valves or moderate-to-severe mitral stenosis are exceptions, as DOACs are contraindicated in those populations [1].

Rivaroxaban (Xarelto)

Rivaroxaban is another Factor Xa inhibitor. Some HPHC formularies place rivaroxaban at a lower tier than apixaban due to rebate negotiations. The ROCKET-AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention in AFib (HR 0.88; 95% CI 0.74 to 1.03; P<0.001 for non-inferiority) [21]. One practical difference: rivaroxaban is dosed once daily, while apixaban requires twice-daily dosing.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor. RE-LY (N=18,113) showed dabigatran 150 mg twice daily was superior to warfarin for stroke prevention in AFib (1.11% vs. 1.69% per year; RR 0.66; 95% CI 0.53 to 0.82; P<0.001) [22]. Dabigatran carries a reversal agent (idarucizumab/Praxbind) that may be relevant for patients at high procedural or trauma risk.

Edoxaban (Savaysa)

Edoxaban is a once-daily Factor Xa inhibitor approved for AFib and VTE. ENGAGE AF-TIMI 48 (N=21,105) demonstrated non-inferiority to warfarin for stroke prevention in AFib and a significantly lower rate of major bleeding [23]. Edoxaban requires an initial parenteral anticoagulant for VTE treatment, which limits its use in some outpatient settings.

Special Populations and Coverage Nuances

Patients with CKD

Apixaban is the preferred DOAC in patients with chronic kidney disease (CKD) stages 3 to 5 based on its predominantly hepatic elimination (approximately 27% renal clearance) [8]. The Kidney Disease Improving Global Outcomes (KDIGO) 2022 guidelines support apixaban use in AFib patients with CKD, including those on dialysis in select circumstances [24]. Documenting CKD in the PA request strengthens the clinical case for apixaban over renally cleared alternatives.

Older Adults and Fall Risk

A common clinical question is whether fall risk justifies withholding anticoagulation. The American Geriatrics Society position, referenced in the ACC guideline, notes that a patient would need to fall approximately 295 times per year for the fall risk to outweigh the stroke-prevention benefit of anticoagulation in high-risk AFib [3]. Including this context in a PA appeal for an elderly patient with a documented high CHA2DS2-VASc score can counter payer hesitancy.

Post-Surgical VTE Prophylaxis

For elective hip or knee arthroplasty, apixaban 2.5 mg twice daily is FDA-approved for 35 days (hip) and 12 days (knee) post-operatively [1]. The ADVANCE-3 trial (N=5,407) showed apixaban reduced the composite of VTE and all-cause mortality by 69% versus enoxaparin after total hip replacement (1.4% vs. 3.9%; RR 0.36; 95% CI 0.22 to 0.54; P<0.001) [25]. Because post-surgical prophylaxis is typically a short course, some HPHC plans provide it without PA when the duration is clearly documented in the claim.

Monitoring and Safety Considerations Your Prescriber Should Document

Unlike warfarin, apixaban requires no routine coagulation monitoring. Annual renal function testing (serum creatinine and calculated eGFR) is appropriate to detect changes that might require dose adjustment or drug discontinuation [8]. The FDA prescribing information specifies dose reduction to apixaban 2.5 mg twice daily when two of three criteria are met: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [1]. Documenting that these criteria have been assessed and the dose is appropriate reinforces the clinical rationale in a PA submission.

Bleeding risk assessment using the HAS-BLED score (hypertension, abnormal renal/liver function, stroke history, bleeding history, labile INR, elderly, drugs/alcohol) should be part of the prescribing decision. A HAS-BLED score of 3 or higher flags patients for modifiable risk factor management rather than automatic anticoagulant discontinuation, per ESC guidelines [26]. That distinction matters in PA documentation: a high HAS-BLED score with modifiable factors addressed is not a contraindication.